Advanced Oncotherapy (LON:AVO) Announces Quarterly Earnings Results, Misses Estimates By $0.93 EPS

Advanced Oncotherapy (LON:AVO) announced its quarterly earnings results on Monday. The company reported GBX (9.83) (($0.12)) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

Shares of LON:AVO opened at GBX 26 ($0.32) on Tuesday. The firm has a fifty day moving average price of GBX 26.68 and a two-hundred day moving average price of GBX 32.10. The company has a debt-to-equity ratio of 55.71, a current ratio of 2.16 and a quick ratio of 0.79. Advanced Oncotherapy has a one year low of GBX 20 ($0.25) and a one year high of GBX 44.50 ($0.55). The company has a market cap of $79.66 million and a price-to-earnings ratio of -1.86.

About Advanced Oncotherapy

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

See Also: Why is a lock-up period needed for an IPO?

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply